FDAnews
www.fdanews.com/articles/81305-nastech-announces-study-results-of-pth1-34-for-osteoporosis

NASTECH ANNOUNCES STUDY RESULTS OF PTH1-34 FOR OSTEOPOROSIS

September 30, 2005

Nastech Pharmaceutical has reported positive results from a Phase I pharmacokinetic study of intranasal Parathyroid Hormone (PTH1-34). The objectives of the study were to determine the nasal absorption and safety of Nastech's PTH1-34 nasal spray versus the approved subcutaneous product, Forteo (teriparatide).

The study achieved its goal of demonstrating the ability to deliver Nastech's intranasal PTH1-34 and produce a similar pharmacokinetic profile to Forteo. Nastech's intranasal PTH1-34 bioavailability program goals were also achieved. The intranasal PTH1-34 formulation was well-tolerated.

The study was conducted in 12 healthy human subjects between the ages of 20 and 40. Each subject received a single subcutaneous injection of Forteo, followed by successive doses of Nastech's intranasal formulation to allow for pharmacokinetic comparison in the same subject. The bioavailability of Nastech's intranasal PTH1-34 formulation relative to the subcutaneous injection was also measured.